Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
LDP-OK’ed Bill for PMD Act Amendment Specifies Launch of Innovative Drug Fund
The health ministry’s draft bill to amend the Pharmaceuticals and Medical Devices (PMD) Act has cleared a ruling party review, setting the stage for its Diet submission. The bill spells out the proposed launch of a government fund for pharmaceutical…
To read the full story
Related Article
- Japan Cabinet Approves Bill to Amend PMD Act
February 13, 2025
- New Govt Fund for Innovative Drugs: Twists, Turns, and Hope
February 10, 2025
- PMD Act Set for Amendments Covering Issues Unaddressed over Past Decade: MHLW Official
February 4, 2025
- Drug Discovery Fund Not Mentioned in Ruling Party Document; All Eyes on Bill’s Review on Jan. 27
January 24, 2025
- MHLW Planning 10-Year Fund for Drug Discovery, Official Reveals at JPMA Meeting
January 24, 2025
- Draft Bill to Amend PMD Act Up for LDP Review on Jan. 27
January 23, 2025
- Nothing Decided on Drug Discovery Support Fund: Minister
January 15, 2025
- FPMAJ Chair Calls for Sufficient Consensus on Drug Discovery Support Fund
January 7, 2025
- PhRMA/EFPIA Lash Out at Japan’s Plan for Mandatory Startup Fund
December 26, 2024
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…